Pro Medicus (ASX:PME) is strengthening its investment in research and development for imaging product, the Visage AI Accelerator platform in the U.S., signing a multi-year agreement with the University of California San Francisco.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The agreement – signed between the university and Pro Medicus’ U.S. subsidiary Visage Imaging, Inc. – will provide a framework through which the two parties will collaborate on the development and commercialisation of the platform, looking specifically into its artificial intelligence capabilities.
It will also build on a relationship already established with UCSF through an existing agreement related to Pro Medicus’ Visage 7 Viewer product.
Visage Imaging Global CTO Malte Westerhoff said the partnership around Visage AI Accelerator was a very important milestone.
“Our AI Accelerator program was designed to closely align Visage’s engineering and product development capability with clinical research partners such as UCSF who have a depth of clinical knowledge and extensive research expertise,” he said.
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
Mr Westerhoff continued: “It provides a unique set of tools for data de-identification, collection, curation, analysis and ‘path-to-production’ in research projects bringing the efficiency and speed of Visage technology to research, resulting in a unified link between the two domains.”
PME shares last traded at $210.32 – a fall of 1.22% since the market opened.
Join the discussion: See what HotCopper users are saying about Pro Medicus and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.